News
SHANGHAI, CHINA, January 3, 2023 – WuXi STA, a subsidiary of WuXi AppTec, today announced that its first drug product Continuous Manufacturing (CM) line for oral solids is in operation at…
SHANGHAI, CHINA, January 3, 2023 – WuXi STA, a subsidiary of WuXi AppTec, today announced that its first drug product Continuous Manufacturing (CM) line for oral solids is in operation at the drug product site located in Wuxi city, China. This new CM line provides global customers an enhanced oral drug development solution, enabling higher yields and shortened timelines to market.
WuXi STA’s continuous manufacturing line features continuous direct compression equipment with unit operations including dispensing, blending, lubrication, tablet compression, and coating. The equipment design complies with the global cGMP regulations. Process Analytical Technology (PAT) is implemented within the CM line to monitor blending uniformity, allowing for real-time analysis and control during production to ensure high product quality.
WuXi STA’s drug product facilities across North America, Europe, and Asia have been inspected by major regulatory agencies including US FDA, EMA, China NMPA, SwissMedic, Japan PMDA, and South Korea MFDS to support global customers with clinical and commercial drug product manufacturing services. The Wuxi city site, where this new CM line was launched, is an integrated formulation development and manufacturing campus with comprehensive analytical platform for both oral and injectable formulations.
Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, commented, “I am glad that our first oral solid-dose drug product continuous manufacturing line has been launched in the Wuxi city site. As a trusted partner and a global enabler, WuXi STA will continue to build first-class facilities with cutting-edge technologies to make more innovative medicines accessible to patients worldwide.”
WuXi STA (stapharma.com), a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations across Asia, North America, and Europe. As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated chemical, manufacturing and controls (CMC) from preclinical to commercial uses, including the development and manufacturing of small molecule, oligonucleotide, peptide and various complex chemical conjugate. For more information, please visit: https://sta.wuxiapptec.com/
Keep reading
Shanghai, China – April 1, 2025 — WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences…
Couvet, Switzerland – November 14, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life…
First operational building dedicated to API development for oligonucleotides, peptides, and complex synthetic conjugates.
How can we help?
Tell us where your molecule is today — discovery, CMC, or commercial supply — and we will map the fastest credible route to patients.
Small molecule projects? WuXi STA